JP2013523636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523636A5 JP2013523636A5 JP2013501293A JP2013501293A JP2013523636A5 JP 2013523636 A5 JP2013523636 A5 JP 2013523636A5 JP 2013501293 A JP2013501293 A JP 2013501293A JP 2013501293 A JP2013501293 A JP 2013501293A JP 2013523636 A5 JP2013523636 A5 JP 2013523636A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- sulfonyl
- phenyl
- benzamide
- pyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 154
- -1 4′-chlorobiphenyl-2-yl Chemical group 0.000 claims description 93
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 38
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 5
- KXCQDIWJQBSUJF-UHFFFAOYSA-N 4-phenyl-1,3-thiazole Chemical compound S1C=NC(C=2C=CC=CC=2)=C1 KXCQDIWJQBSUJF-UHFFFAOYSA-N 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 239000000651 prodrug Chemical class 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- QAFBPROQQSGNKK-UHFFFAOYSA-N 1-(1-adamantyl)-4-[2-[[4-[4-[[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylcarbamoyl]phenyl]piperazin-1-yl]methyl]phenyl]-n,n-diphenylpyrazole-3-carboxamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C(=NN(C=3)C34CC5CC(CC(C5)C3)C4)C(=O)N(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCC1CCOCC1 QAFBPROQQSGNKK-UHFFFAOYSA-N 0.000 claims description 2
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 claims description 2
- KGQKHDAFBKFNHO-UHFFFAOYSA-N 6-[3-(1-adamantyl)-4-hydroxyphenyl]-n-[4-(cyclohexylmethylamino)-3-nitrophenyl]sulfonylnaphthalene-2-carboxamide Chemical compound C1=C(C23CC4CC(CC(C4)C2)C3)C(O)=CC=C1C(C=C1C=C2)=CC=C1C=C2C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCCCC1 KGQKHDAFBKFNHO-UHFFFAOYSA-N 0.000 claims description 2
- WTIWXNQNRBTBKY-UHFFFAOYSA-N 6-[3-(1-adamantyl)-4-methoxyphenyl]-n-[4-(cyclohexylmethylamino)-3-nitrophenyl]sulfonylnaphthalene-2-carboxamide Chemical compound C1=C(C23CC4CC(CC(C4)C2)C3)C(OC)=CC=C1C(C=C1C=C2)=CC=C1C=C2C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCCCC1 WTIWXNQNRBTBKY-UHFFFAOYSA-N 0.000 claims description 2
- CHWWMJVEPPORKA-UHFFFAOYSA-N C12(CC3CC(CC(C1)C3)C2)CNC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C2=CC=C(C=C2)C=2C=CC3=C(N=C(S3)CCCC)C2)[N+](=O)[O-] Chemical compound C12(CC3CC(CC(C1)C3)C2)CNC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C2=CC=C(C=C2)C=2C=CC3=C(N=C(S3)CCCC)C2)[N+](=O)[O-] CHWWMJVEPPORKA-UHFFFAOYSA-N 0.000 claims description 2
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 claims description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- YCGAILBJRWNKLY-UHFFFAOYSA-N n-[1-[4-[[3-nitro-4-(oxan-4-ylamino)phenyl]sulfonylcarbamoyl]phenyl]piperidin-4-yl]adamantane-1-carboxamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC2)NC(=O)C23CC4CC(CC(C4)C2)C3)=CC=C1NC1CCOCC1 YCGAILBJRWNKLY-UHFFFAOYSA-N 0.000 claims description 2
- AJZLLBZLGGUXKR-UHFFFAOYSA-N n-cyclooctyl-5-[2-[[4-[4-[[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylcarbamoyl]phenyl]piperazin-1-yl]methyl]phenyl]furan-2-carboxamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3OC(=CC=3)C(=O)NC3CCCCCCC3)CC2)=CC=C1NCC1CCOCC1 AJZLLBZLGGUXKR-UHFFFAOYSA-N 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 201000006491 bone marrow cancer Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000025113 myeloid leukemia Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 201000002471 spleen cancer Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000527 lymphocytic effect Effects 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- SAGLDTPKDYZPNX-UHFFFAOYSA-N oct-3-enamide Chemical compound CCCCC=CCC(N)=O SAGLDTPKDYZPNX-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- VMJGNWWGAXVEOP-UHFFFAOYSA-N bicyclo[2.2.1]hept-2-ene-4-carboxamide Chemical compound C1CC2C=CC1(C(=O)N)C2 VMJGNWWGAXVEOP-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31757510P | 2010-03-25 | 2010-03-25 | |
| US61/317,575 | 2010-03-25 | ||
| PCT/US2011/027895 WO2011119345A2 (en) | 2010-03-25 | 2011-03-10 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523636A JP2013523636A (ja) | 2013-06-17 |
| JP2013523636A5 true JP2013523636A5 (enExample) | 2016-06-16 |
| JP5959501B2 JP5959501B2 (ja) | 2016-08-02 |
Family
ID=43858249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501293A Expired - Fee Related JP5959501B2 (ja) | 2010-03-25 | 2011-03-10 | 癌ならびに免疫および自己免疫疾患の治療のためのアポトーシス誘導物質 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8188077B2 (enExample) |
| EP (3) | EP2550258B1 (enExample) |
| JP (1) | JP5959501B2 (enExample) |
| KR (1) | KR20130040834A (enExample) |
| CN (2) | CN105218483A (enExample) |
| AU (1) | AU2011229862B2 (enExample) |
| BR (1) | BR112012024382A2 (enExample) |
| CA (1) | CA2792276A1 (enExample) |
| DK (1) | DK2550258T3 (enExample) |
| ES (1) | ES2553143T3 (enExample) |
| HK (2) | HK1200444A1 (enExample) |
| HR (1) | HRP20151218T1 (enExample) |
| HU (1) | HUE026241T2 (enExample) |
| IL (2) | IL221771A (enExample) |
| MX (1) | MX2012011086A (enExample) |
| NZ (2) | NZ628298A (enExample) |
| PL (1) | PL2550258T3 (enExample) |
| PT (1) | PT2550258E (enExample) |
| RS (1) | RS54388B1 (enExample) |
| RU (2) | RU2015141713A (enExample) |
| SG (2) | SG184094A1 (enExample) |
| SI (1) | SI2550258T1 (enExample) |
| SM (1) | SMT201600016B (enExample) |
| TW (2) | TW201623291A (enExample) |
| WO (1) | WO2011119345A2 (enExample) |
| ZA (1) | ZA201206837B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| NZ616828A (en) | 2009-01-19 | 2015-03-27 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| CA2859385A1 (en) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| CA2874621A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| US9359367B2 (en) | 2012-07-09 | 2016-06-07 | Lupin Limited | Tetrahydroquinazolinone derivatives as PARP inhibitors |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| KR101643280B1 (ko) * | 2014-09-02 | 2016-07-28 | 한국원자력의학원 | 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피페리딘카복사마이드 유도체 및 이의 의학적 용도 |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| FI3381896T3 (fi) * | 2015-11-27 | 2023-04-21 | Taiho Pharmaceutical Co Ltd | Bifenyyliyhdiste tai sen suola |
| KR102359439B1 (ko) * | 2017-03-31 | 2022-02-09 | (주)아모레퍼시픽 | 벤조산아마이드 화합물 및 사이클로덱스트린 용해보조제를 포함하는 조성물 |
| WO2018216795A1 (ja) * | 2017-05-26 | 2018-11-29 | 大鵬薬品工業株式会社 | 新規なビフェニル化合物を用いた抗腫瘍効果増強剤 |
| GB201716871D0 (en) * | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| CN112437772B (zh) | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| RU2693378C1 (ru) * | 2018-10-02 | 2019-07-02 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Фармацевтическая композиция, проявляющая цитотоксическое действие в отношении клеток рака мочевого пузыря человека |
| SG11202113092WA (en) * | 2019-06-10 | 2021-12-30 | Adc Therapeutics Sa | Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| CN116969937B (zh) | 2020-04-15 | 2026-03-24 | 百济神州(苏州)生物科技有限公司 | Bcl-2抑制剂 |
| CN114835704B (zh) * | 2021-02-01 | 2023-10-27 | 苏州亚盛药业有限公司 | 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物 |
| BR112023017371A2 (pt) | 2021-03-19 | 2023-10-03 | Eil Therapeutics Inc | Compostos que têm ((3-nitrofenil)sulfonil)acetamida como inibidores de bcl-2 |
| WO2024032776A1 (en) * | 2022-08-12 | 2024-02-15 | Fochon Biosciences, Ltd. | Compounds as bcl-2 inhibitors |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5892655A (ja) * | 1981-11-27 | 1983-06-02 | Otsuka Chem Co Ltd | カ−バメイト系誘導体、その製造方法及びその誘導体を有効成分として含有する殺虫剤 |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| US6277985B1 (en) | 1995-09-15 | 2001-08-21 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone N-oxides |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| UY26942A1 (es) * | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6720338B2 (en) * | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US20050049594A1 (en) * | 2001-04-20 | 2005-03-03 | Wack Michael A. | Dual locking plate and associated method |
| SK14642003A3 (sk) * | 2001-06-06 | 2004-12-01 | Eli Lilly And Company | Benzoylsulfónamidy a sulfonylbenzamidíny ako protinádorové činidlá |
| AU4235802A (en) * | 2002-05-20 | 2003-11-27 | Andreas Krumbacher | Combinations flexible apparatus (multiple flexibletrack) |
| DE60316984T2 (de) * | 2002-11-22 | 2008-07-17 | Eli Lilly And Co., Indianapolis | Benzoylsulfonamide als antitumor-mittel |
| JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
| US8614318B2 (en) * | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| ES2294494T3 (es) | 2004-04-19 | 2008-04-01 | Symed Labs Limited | Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados. |
| ATE542796T1 (de) * | 2004-05-26 | 2012-02-15 | Abbott Lab | N-sulfonylcarboximidamidverbindungen als apoptosepromotoren |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| US20060088886A1 (en) * | 2004-10-25 | 2006-04-27 | Anlong Ouyang | Topiramate analogs |
| ES2493466T3 (es) * | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| US20080182845A1 (en) * | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| WO2009036035A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| WO2009055006A1 (en) | 2007-10-26 | 2009-04-30 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| NZ585085A (en) * | 2007-11-16 | 2012-08-31 | Abbott Lab | Method of treating arthritis using arylsulfonamide compounds |
| US20100160322A1 (en) * | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) * | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| NZ616828A (en) * | 2009-01-19 | 2015-03-27 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| RU2538965C2 (ru) * | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
-
2011
- 2011-03-10 AU AU2011229862A patent/AU2011229862B2/en not_active Ceased
- 2011-03-10 EP EP11709579.4A patent/EP2550258B1/en active Active
- 2011-03-10 RU RU2015141713A patent/RU2015141713A/ru unknown
- 2011-03-10 SI SI201130660T patent/SI2550258T1/sl unknown
- 2011-03-10 CA CA2792276A patent/CA2792276A1/en not_active Abandoned
- 2011-03-10 HR HRP20151218TT patent/HRP20151218T1/hr unknown
- 2011-03-10 PT PT117095794T patent/PT2550258E/pt unknown
- 2011-03-10 BR BR112012024382A patent/BR112012024382A2/pt not_active IP Right Cessation
- 2011-03-10 EP EP15178279.4A patent/EP2957558A3/en not_active Withdrawn
- 2011-03-10 NZ NZ628298A patent/NZ628298A/en not_active IP Right Cessation
- 2011-03-10 RS RS20150756A patent/RS54388B1/sr unknown
- 2011-03-10 PL PL11709579T patent/PL2550258T3/pl unknown
- 2011-03-10 DK DK11709579.4T patent/DK2550258T3/en active
- 2011-03-10 CN CN201510587254.2A patent/CN105218483A/zh active Pending
- 2011-03-10 JP JP2013501293A patent/JP5959501B2/ja not_active Expired - Fee Related
- 2011-03-10 KR KR1020127027672A patent/KR20130040834A/ko not_active Ceased
- 2011-03-10 WO PCT/US2011/027895 patent/WO2011119345A2/en not_active Ceased
- 2011-03-10 NZ NZ602055A patent/NZ602055A/en not_active IP Right Cessation
- 2011-03-10 HU HUE11709579A patent/HUE026241T2/en unknown
- 2011-03-10 ES ES11709579.4T patent/ES2553143T3/es active Active
- 2011-03-10 RU RU2012145298/04A patent/RU2568611C2/ru not_active IP Right Cessation
- 2011-03-10 SG SG2012068615A patent/SG184094A1/en unknown
- 2011-03-10 EP EP14160660.8A patent/EP2757105A1/en not_active Withdrawn
- 2011-03-10 SG SG10201406608YA patent/SG10201406608YA/en unknown
- 2011-03-10 CN CN201180015915.4A patent/CN102947283B/zh not_active Expired - Fee Related
- 2011-03-10 MX MX2012011086A patent/MX2012011086A/es active IP Right Grant
- 2011-03-16 US US13/049,569 patent/US8188077B2/en not_active Expired - Fee Related
- 2011-03-25 TW TW105106938A patent/TW201623291A/zh unknown
- 2011-03-25 TW TW100110483A patent/TWI535713B/zh not_active IP Right Cessation
-
2012
- 2012-04-27 US US13/458,968 patent/US8343967B2/en not_active Expired - Fee Related
- 2012-09-04 IL IL221771A patent/IL221771A/en not_active IP Right Cessation
- 2012-09-12 ZA ZA2012/06837A patent/ZA201206837B/en unknown
-
2013
- 2013-06-06 HK HK15100726.4A patent/HK1200444A1/en unknown
-
2014
- 2014-03-25 IL IL231702A patent/IL231702A0/en unknown
-
2016
- 2016-01-15 SM SM201600016T patent/SMT201600016B/it unknown
- 2016-06-17 HK HK16107017.6A patent/HK1219092A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012145298A (ru) | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний | |
| JP2013512899A5 (enExample) | ||
| JP2013527202A5 (enExample) | ||
| JP2022043059A5 (enExample) | ||
| EP3931183B1 (en) | Compounds with ferroptosis inducing activity and methods of their use | |
| HRP20230294T1 (hr) | Modulatori tmem16a | |
| RU2012127790A (ru) | Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2013507449A5 (enExample) | ||
| JP2021515004A5 (enExample) | ||
| JP2005521639A5 (enExample) | ||
| JP2010504342A5 (enExample) | ||
| JP2021515033A5 (enExample) | ||
| JP2006514925A5 (enExample) | ||
| RU2011127402A (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| JP2018529770A5 (enExample) | ||
| KR20230002483A (ko) | Bcl-2 단백질 억제제 | |
| RU2014121984A (ru) | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств | |
| JP2020506171A5 (enExample) | ||
| JP2013510883A5 (enExample) | ||
| JP2013512900A5 (enExample) | ||
| JP2009512659A5 (enExample) | ||
| JP2016503009A5 (enExample) | ||
| HRP20150925T1 (hr) | Agensi koji induciraju apoptozu za lijeäśenje raka te imunih i autoimunih bolesti | |
| JP2011524906A5 (enExample) | ||
| NZ617334A (en) | Cyclopropyl amine derivatives |